How Social Security COLA Could Move Cencora Stock And Senior Healthcare Demand

Retirement costs are climbing, Social Security’s projected 2027 COLA sits near the mid 3% range, and about 70 million Americans could see more cash flowing into their bank accounts. That extra income often finds its way into healthcare and everyday services, which can reshape demand for certain senior focused businesses. This article walks through three stocks exposed to this COLA story and explains why their reaction to it deserves attention.

The three stocks covered below are only a sample set, and the full screen surfaced 13 more U.S. senior healthcare and Medicare exposed companies with equally compelling narratives that are not included here.

If you want to identify potential higher conviction ideas across this theme, head straight into the U.S. Senior Healthcare & Medicare-Exposed Companies screener to filter and analyze the wider group for yourself.

Janus Living (JAN)

Janus Living is a pure-play senior housing REIT serving older Americans in key retirement markets, with 69% of its 10,422 units in Florida and Texas. The business generated about US$723 million from senior housing in the United States and carries a market value of roughly US$9.3b.

For investors focused on seniors and Medicare-linked demand, Janus Living offers concentrated exposure to private-pay senior housing. In this model, resident fees, rather than government reimbursement, underpin cash flows. This structure makes the projected COLA-driven income lift for retirees especially relevant if a single key assumption on funding costs and occupancy pressure changes.

If that funding and occupancy equation is what you care about, read the 3 key rewards and 2 important warning signs to see what might accelerate or stall Janus Living’s story.

National Healthcare Properties (NHP)

National Healthcare Properties focuses on senior housing and outpatient medical facilities tied to older adults’ care needs, generating about US$229 million from senior housing and US$115 million from outpatient sites, all in the US. The REIT carries a market value near US$1.02 billion.

For investors following the seniors and Medicare theme, National Healthcare Properties links directly to how rental affordability and care access respond to higher transfer income for older Americans as Social Security COLA projections move higher.

"Although the company has expanded its credit facility to US$1.2b and reduced leverage to 4.6x net debt to annualized further adjusted EBITDA, the plan to fund a sizeable acquisition pipeline and preferred redemptions through the revolver and equity units could increase financing costs and equity dilution."

What happens to National Healthcare Properties’ earnings path if a single pressure point in that funding plan starts to squeeze margins harder than expected?

If that margin squeeze is what you are worrying about, read the full narrative for National Healthcare Properties to see whether funding risks are masking a stronger income story ahead.

Cencora (COR)

Cencora quietly powers a large share of the U.S. medicine cabinet, and a meaningful slice of that demand comes from older adults whose prescriptions are often tied to Medicare. That senior tilt is why the stock fits this screener and why its latest move in specialty services matters.

Cencora is a global pharmaceutical distributor and services provider, with U.S. Healthcare Solutions generating about US$300.1b in revenue and International Healthcare Solutions contributing roughly US$32.3b. The business, valued near US$58.9b, is deeply linked to senior and Medicare-driven prescription volumes.

"Cencora’s Accelerate Pharmacy Solutions unit launched a Cell and Gene Therapy Enablement service that is designed to help health systems build and scale cell and gene therapy programs, with tailored support around financial confidence, operational readiness and scalable growth."

What happens if a single assumption about how quickly high touch specialty therapies scale through Cencora’s network shifts in either direction?

If that shift in specialty momentum is on your radar, the full narrative for Cencora breaks down where Cencora’s senior-linked engine could be accelerating or masking bigger risks.

Seeking Alternatives Before The Crowd

Fresh themes form, momentum builds, and then the best ideas start flying once everyone has already caught on. Scan these under the radar lists while it matters and get in early.

• Spot steady compounders with pricing power and robust balance sheets by running the list of solid balance sheet and fundamentals (23 results) before others notice the stronger fundamentals.
• Chase early breakout potential in miners by reviewing the 36 elite gold producer stocks while many investors still overlook the producers behind bullion headlines.
• Track infrastructure momentum by scanning the 39 power grid technology and infrastructure stocks before capital flows to the companies upgrading aging networks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com